Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016
Published Sep 30, 2016
63 pages — Published Sep 30, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy (PDR) Pipeline Review, H2 2016, provides an overview of the Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline landscape.

Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision and difficulty with color perception.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy (PDR) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 4 and 1 respectively for Proliferative Diabetic Retinopathy (PDR).

Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Proliferati

  
Source:
Document ID
GMDHC8509IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Proliferative Diabetic Retinopathy (PDR) Overview61
Therapeutics Development71
  Pipeline Products for Proliferative Diabetic Retinopathy (PDR) Overview71
Proliferative Diabetic Retinopathy (PDR) Therapeutics under Development by Companies81
Proliferative Diabetic Retinopathy (PDR) Pipeline Products Glance92
  Clinical Stage Products91
  Early Stage Products101
Proliferative Diabetic Retinopathy (PDR) Products under Development by Companies111
Proliferative Diabetic Retinopathy (PDR) Companies Involved in Therapeutics Development129
  Acucela Inc.121
  Aerie Pharmaceuticals, Inc.131
  Antisense Therapeutics Limited141
  Icon Bioscience, Inc.151
  OcuCure Therapeutics, Inc.161
  Ohr Pharmaceutical Inc.171
  PanOptica, Inc.181
  Ribomic Inc.191
  ThromboGenics NV201
Proliferative Diabetic Retinopathy (PDR) Therapeutics Assessment219
  Assessment by Monotherapy Products211
  Assessment by Target222
  Assessment by Mechanism of Action242
  Assessment by Route of Administration262
  Assessment by Molecule Type282
Drug Profiles3030
  AR-13154 Drug Profile301
  atesidorsen sodium Drug Profile317
  cyclosporine Drug Profile381
  emixustat hydrochloride Drug Profile394
  OC-10X Drug Profile431
  ocriplasmin Drug Profile445
  OLX-302 Drug Profile491
  PAN-90806 Drug Profile502
  RBM-008 Drug Profile521
  squalamine lactate Drug Profile537
Proliferative Diabetic Retinopathy (PDR) Dormant Projects601
Proliferative Diabetic Retinopathy (PDR) Product Development Milestones611
  Featured News &Press Releases611
    May 08, 2016: Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy611
Appendix622
  Methodology621
  Coverage621
  Secondary Research621
  Primary Research621
  Expert Panel Validation621
  Contact Us621
  Disclaimer631

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016" Sep 30, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Proliferative-Diabetic-Retinopathy-PDR-Pipeline-Review-H2-2016-2088-16636>
  
APA:
Global Markets Direct - Market Research. (2016). Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016 Sep 30, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Proliferative-Diabetic-Retinopathy-PDR-Pipeline-Review-H2-2016-2088-16636>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.